Clinical trials: Left Ventricular Failure
Pulmonary Edema Cardiac Cause
Cosmic Weather and Cardiogenic Pulmonary Edema
Retrospective clinical study to evaluate whether there is any correlation between the pre-hospital incidence of cardiogenic pulmonary oedema (CPE) in the selected region and the space weather parameters.
- Trial name
- NCT04483843
- Testing
- No intervention
- Where
- Czechia
- Volunteers
- 4,000 people
- Sponsor
- Emergency Medical Service of the Central Bohemian Region, Czech Republic
Heart Failure
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
The purpose of this open-label study was to collect additional safety information of sacubitril/valsartan and to provide post-trial access to sacubitril/valsartan for the eligible Japanese patients who completed…
- Trial name
- NCT06149104
- Testing
- sacubitril/valsartan
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive
The FOCUS-ADHF Registry
Acute heart failure (AHF) represents a significant clinical and economic burden due to its impact on patients' quality of life, poor prognosis, and high healthcare costs.
- Conditions
- Acute Heart Failure With Reduced Ejection Fraction, Decompensation; Heart, Congestive, Regurgitation, Mitral
- Trial name
- FOCUS-ADHF (NCT06726109)
- Where
- 4 sites in Belgium, Italy
- Volunteers
- 600 people
- Sponsor
- ASL Città di Torino
Breast Cancer, Heart Failure
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned.
- Trial name
- SCHOLAR-2 (NCT04680442)
- Testing
- Trastuzumab, Pertuzumab, Trastuzumab emtansine
- Where
- 8 sites in Brazil, Canada and 1 more
- Volunteers
- 130 people
- Sponsor
- Population Health Research Institute
Left Ventricular Myocardial Dysfunction, End-Stage Kidney Disease
Assessment of Left Ventricular Myocardial Dysfunction in Children With End-Stage Kidney Disease Using Two-Dimensional and Three-Dimensional Speckle-Tracking Echocardiography
The present study aimed to assess left ventricular myocardial dysfunction in children with chronic kidney disease using 2D and 3D speckle-tracking echocardiography.
- Conditions
- Left Ventricular Myocardial Dysfunction, End-Stage Kidney Disease, Two-Dimensional Speckle-Tracking Echocardiography, Three-Dimensional Speckle-Tracking Echocardiography
- Trial name
- NCT07678710
- Testing
- Two-Dimensional Speckle-Tracking Echocardiography (2D-STE), Three-Dimensional Speckle-Tracking Echocardiography (3D-STE)
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Al-Azhar University
Heart Failure
LV Dysfunction Following Pacemaker Placement
Several studies have confirmed the link between chronic RV apical pacing and the development of heart failure and LV systolic dysfunction in some patients 1,2.
- Trial name
- NCT03850808
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Oregon Health and Science University
Right Heart Failure
Accelerated LBBP for Patients With RHF and Severe TR
This study is a prospective, single-arm, target value clinical trial. We plan to prospectively enroll and follow 24 patients across three centers nationwide who have a low baseline heart rate (HR ≤ 60 bpm), meet the indication…
- Trial name
- ARCP (NCT07470047)
- Testing
- permanent pacemaker implantation
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Shanghai Zhongshan Hospital
Transcatheter Aortic Valve Replacement
Prognostic Factors in NOP-LBBB After TAVI
The goal of this observational study is to find prognostic factors in patients with a new-onset persistent left bundle branch block (NOP-LBBB) after transcatheter aortic valve implantation (TAVI).
- Trial name
- ProgNOP-LBBB (NCT05654792)
- Testing
- Transcatheter aortic valve implantation
- Volunteers
- 230 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure
Model 4396 Left Ventricular (LV) Lead Chronic Performance Study
Lead survivability will be summarized.
- Trial name
- NCT01361685
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 366 people
- Sponsor
- Medtronic
Congestive Heart Failure
The Effect of Left Ventricular Filling Pressure on Pulmonary Clearance of Free Radical Loaded White Blood Cells and Platelets in Congestive Heart Failure Patients Before and After Biventricular Pacing
1. To assess whether a correlation exist between the degree of pulmonary clearance of free radical positive white bloodcells and platelets and the degree of pulmonary congestion in congestive heart failure (CHF) patients 2.
- Trial name
- OXIS-PACING (NCT00716885)
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Heart Failure, Left-Sided, Heart Failure, Right-Sided
Central and Cerebral Circulation in Early Stages After LVAD Implantation
This trial will evaluate patients with a mechanical Left Ventricular Assist Device (LVAD) in early stages after surgical implantation.
- Trial name
- ECOH3 (NCT03087669)
- Testing
- LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®, MAP intervention using Noradrenalin
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Sahlgrenska University Hospital
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Hypotension, Heart Failure
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy
The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure events and cardiovascular death comparing to placebo in patients with reduced ejection fraction further to standard of care.
- Trial name
- NCT04575675
- Testing
- Dapagliflozin, Sacubitril-Valsartan, Beta blocker
- Where
- Taiwan
- Volunteers
- 78 people
- Sponsor
- Cheng-Hsin General Hospital
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children and young adults who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORELLO (NCT07192952)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 132 sites in United States, Argentina and 21 more
- Volunteers
- 117 people
- Sponsor
- Bayer
Heart Failure, Heart Murmurs
Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients
This is a retrospective chart review examining our experience with carvedilol in CHF secondary to left-to-right heart shunt lesions. The treatment group will be children who have received carvedilol.
- Trial name
- NCT00249067
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Children's Healthcare of Atlanta
Heart Failure
Pacing in Heart Failure With Preserved LVEF
A random-order cross-over pilot trial of a CE marked device (pacemaker) outside its current intended purposes. The study will comprise 10 patients.
- Trial name
- MAPPLE (NCT03215849)
- Testing
- CRT-pacemaker device set to Routine Medical Therapy, CRT-pacemaker device set to Routine Medical Therapy + LVP, CRT-pacemaker device set to Routine Medical Therapy + BiVP
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Cardiff and Vale University Health Board
Heart Failure, Breast Cancer
Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2
Trastuzumab is an important treatment for HER 2 positive breast cancer. But trastuzumab can cause injury to the heart, and this is one of the main reasons it cannot be administered as planned.
- Trial name
- SCHOLAR (NCT02907021)
- Testing
- standard-of-care treatments for LV impairment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Population Health Research Institute
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD).
- Trial name
- FIORE (NCT07188805)
- Testing
- Finerenone (Kerendia, BAY94-8862)
- Where
- 133 sites in United States, Argentina and 21 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Heart Failure
Model 4196 Left Ventricular (LV) Lead Chronic Performance Study
The purpose of this study is to evaluate long-term performance of the 4196 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the…
- Trial name
- NCT00930904
- Where
- 103 sites in United States, Austria and 6 more
- Volunteers
- 1,847 people
- Sponsor
- Medtronic
Dilated Cardiomyopathy
Reverse Remodelling and Remission Markers in the Serial Evaluation of Recent-onset Dilated Cardiomyopathy
Approximately 30-40% of patients with non-ischaemic dilated cardiomyopathy (DCM) undergo significant left ventricular reverse remodelling in response to guideline-directed therapies.
- Trial name
- REMIT-DCM (NCT04957147)
- Testing
- 12 months of guideline-directed heart failure therapy
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Imperial College London